Cargando…

YKL-40 as a possible marker of neutrophilic asthma

Asthma is a heterogeneous chronic disorder of the airways, with inflammation and bronchial hyperresponsiveness as its major underlying phenomena. Asthmatics vary in terms of inflammation pattern, concomitant pathologies, and factors aggravating the course of the disease. As a result, there is a need...

Descripción completa

Detalles Bibliográficos
Autores principales: Specjalski, Krzysztof, Romantowski, Jan, Niedoszytko, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945318/
https://www.ncbi.nlm.nih.gov/pubmed/36844232
http://dx.doi.org/10.3389/fmed.2023.1115938
_version_ 1784892116300726272
author Specjalski, Krzysztof
Romantowski, Jan
Niedoszytko, Marek
author_facet Specjalski, Krzysztof
Romantowski, Jan
Niedoszytko, Marek
author_sort Specjalski, Krzysztof
collection PubMed
description Asthma is a heterogeneous chronic disorder of the airways, with inflammation and bronchial hyperresponsiveness as its major underlying phenomena. Asthmatics vary in terms of inflammation pattern, concomitant pathologies, and factors aggravating the course of the disease. As a result, there is a need for sensitive and specific biomarkers that could facilitate diagnosing asthma as well as phenotyping in everyday practice. Chitinases and chitinase-like proteins (CLPs) seem promising in this field. Chitinases are evolutionarily conserved hydrolases that degrade chitin. In contrast, CLPs bind chitin but do not have degrading activity. Mammalian chitinases and CLPs are produced by neutrophils, monocytes, and macrophages in response to parasitic or fungal infections. Recently, several questions have been raised about their role in chronic airway inflammation. Several studies demonstrated that overexpression of CLP YKL-40 was associated with asthma. Moreover, it correlated with exacerbation rate, therapy resistance, poor control of symptoms, and, inversely, with FEV(1). YKL-40 facilitated allergen sensitization and IgE production. Its concentration was elevated in bronchoalveolar lavage fluid after an allergen challenge. It was also found to promote the proliferation of bronchial smooth muscle cells and correlate with subepithelial membrane thickness. Thus, it may be involved in bronchial remodeling. Associations between YKL-40 and particular asthma phenotypes remain unclear. Some studies showed that YKL-40 correlates with blood eosinophilia and FeNO, suggesting a role in T2-high inflammation. Quite the opposite, cluster analyses revealed the highest upregulation in severe neutrophilic asthma and obesity-associated asthma. The main limitation in the practical application of YKL-40 as a biomarker is its low specificity. High serum levels of YKL-40 were also found in COPD and several malignancies, in addition to infectious and autoimmune diseases. To conclude, the level of YKL-40 correlates with asthma and some clinical features in the whole asthmatic population. The highest levels are found in neutrophilic and obesity-related phenotypes. However, due to its low specificity, the practical application of YKL-40 remains uncertain but could be useful in phenotyping, especially when combined with other biomarkers.
format Online
Article
Text
id pubmed-9945318
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99453182023-02-23 YKL-40 as a possible marker of neutrophilic asthma Specjalski, Krzysztof Romantowski, Jan Niedoszytko, Marek Front Med (Lausanne) Medicine Asthma is a heterogeneous chronic disorder of the airways, with inflammation and bronchial hyperresponsiveness as its major underlying phenomena. Asthmatics vary in terms of inflammation pattern, concomitant pathologies, and factors aggravating the course of the disease. As a result, there is a need for sensitive and specific biomarkers that could facilitate diagnosing asthma as well as phenotyping in everyday practice. Chitinases and chitinase-like proteins (CLPs) seem promising in this field. Chitinases are evolutionarily conserved hydrolases that degrade chitin. In contrast, CLPs bind chitin but do not have degrading activity. Mammalian chitinases and CLPs are produced by neutrophils, monocytes, and macrophages in response to parasitic or fungal infections. Recently, several questions have been raised about their role in chronic airway inflammation. Several studies demonstrated that overexpression of CLP YKL-40 was associated with asthma. Moreover, it correlated with exacerbation rate, therapy resistance, poor control of symptoms, and, inversely, with FEV(1). YKL-40 facilitated allergen sensitization and IgE production. Its concentration was elevated in bronchoalveolar lavage fluid after an allergen challenge. It was also found to promote the proliferation of bronchial smooth muscle cells and correlate with subepithelial membrane thickness. Thus, it may be involved in bronchial remodeling. Associations between YKL-40 and particular asthma phenotypes remain unclear. Some studies showed that YKL-40 correlates with blood eosinophilia and FeNO, suggesting a role in T2-high inflammation. Quite the opposite, cluster analyses revealed the highest upregulation in severe neutrophilic asthma and obesity-associated asthma. The main limitation in the practical application of YKL-40 as a biomarker is its low specificity. High serum levels of YKL-40 were also found in COPD and several malignancies, in addition to infectious and autoimmune diseases. To conclude, the level of YKL-40 correlates with asthma and some clinical features in the whole asthmatic population. The highest levels are found in neutrophilic and obesity-related phenotypes. However, due to its low specificity, the practical application of YKL-40 remains uncertain but could be useful in phenotyping, especially when combined with other biomarkers. Frontiers Media S.A. 2023-02-08 /pmc/articles/PMC9945318/ /pubmed/36844232 http://dx.doi.org/10.3389/fmed.2023.1115938 Text en Copyright © 2023 Specjalski, Romantowski and Niedoszytko. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Specjalski, Krzysztof
Romantowski, Jan
Niedoszytko, Marek
YKL-40 as a possible marker of neutrophilic asthma
title YKL-40 as a possible marker of neutrophilic asthma
title_full YKL-40 as a possible marker of neutrophilic asthma
title_fullStr YKL-40 as a possible marker of neutrophilic asthma
title_full_unstemmed YKL-40 as a possible marker of neutrophilic asthma
title_short YKL-40 as a possible marker of neutrophilic asthma
title_sort ykl-40 as a possible marker of neutrophilic asthma
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945318/
https://www.ncbi.nlm.nih.gov/pubmed/36844232
http://dx.doi.org/10.3389/fmed.2023.1115938
work_keys_str_mv AT specjalskikrzysztof ykl40asapossiblemarkerofneutrophilicasthma
AT romantowskijan ykl40asapossiblemarkerofneutrophilicasthma
AT niedoszytkomarek ykl40asapossiblemarkerofneutrophilicasthma